Prognosis
Future of Covid Boosters Comes Down to Crucial Meeting of FDA Advisers
- Scientists to debate when, and to whom, to give more shots
- Annual vaccination could reap billions for drugmakers
This article is for subscribers only.
An all-star panel of Covid experts is gathering Wednesday to hash out how and when vaccines should be updated to address future variants as the virus continues to rapidly mutate.
The meeting of U.S. Food and Drug Administration advisers should provide some of the first hints of its strategy to map out a more proactive plan for developing strain-specific boosters. Until now, the process has been led by drugmakers such as Moderna Inc. and Pfizer Inc., which have gained approval for boosters for specific populations.